David Erick Wright
16Patents
5h-index
5Co-inventors
59Inventor score
Filing activity: Sep 30, 1985 → Apr 9, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9377454B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | Physics | 25 | Active |
| US4742156A | Peptide antagonists of neurokinin B and opthalmic solutions containing them | Human Necessities | 24 | Expired |
| US4665157A | Peptide antagonists of neurokinin B | Human Necessities | 9 | Expired |
| US10139399B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy | Physics | 8 | Active |
| US10823727B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | Physics | 8 | Active |
| US11639927B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy | Physics | 4 | Active |
| US11598767B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | Physics | 3 | Active |
| US6458357B1 | Retro-inverso neurotrophic and analgesic peptides | Human Necessities | 2 | Expired |
| US7135461B1 | Retro-inverso peptides derived from interleukin-6 | Chemistry; Metallurgy | 2 | Expired |
| US7115571B1 | Retro-inverso peptides derived from interleukin-3 | Human Necessities | 2 | Expired |
| US7109168B1 | Retro-inverso peptides derived from leukemia inhibitory factor | Chemistry; Metallurgy | 1 | Expired |
| US7754688B2 | Methods of using retro-inverso peptides derived from interleukin-6 | Chemistry; Metallurgy | 1 | Active |
| US11982670B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | Physics | 0 | Active |
| US12188927B2 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy | Physics | 0 | Active |
| US8063016B2 | Retro-inverso peptides derived from interleukin-6 | Chemistry; Metallurgy | 0 | Active |
| US7754690B2 | Method of using retro inverso peptides derived from leukemia inhibitory factor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.